← Eichor
Study identifier: NCT05995353 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Condition: Crohn's Disease  ·  Sponsor: AbbVie

PhasePhase 3
Planned participants110
Who can joinAll sexes, 2 Years to 17 Years
Healthy volunteersNo

About this study

Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to \< 18 years old who have had intolerance or inadequate response to other therapies. Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 110 pediatric participants with CD will be enrolled at around 100 sites worldwide. Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneous…

This description comes directly from the study's public registry record.

Talk to the study team

ABBVIE CALL CENTER  ·  844-663-3742  ·  abbvieclinicaltrials@abbvie.com

Always discuss trial participation with your own doctor first.

Locations (85)

Phoenix Children's Hospital /ID# 255766Phoenix, Arizona, United StatesRecruiting
Arkansas Children's Hospital /ID# 255762Little Rock, Arkansas, United StatesRecruiting
UCSF Benioff Children's Hospital - Oakland /ID# 258327Oakland, California, United StatesRecruiting
Children's Hospital Colorado - Aurora /ID# 255764Aurora, Colorado, United StatesRecruiting
Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437Orlando, Florida, United StatesRecruiting
Indiana University Health Riley Hospital for Children /ID# 256454Indianapolis, Indiana, United StatesRecruiting
Massachusetts General Hospital /ID# 255767Boston, Massachusetts, United StatesRecruiting
MNGI Digestive Health, P. A. /ID# 255366Minneapolis, Minnesota, United StatesRecruiting
Goryeb Childrens Hospital /ID# 256452Morristown, New Jersey, United StatesRecruiting
Icahn School of Medicine at Mount Sinai /ID# 254880New York, New York, United StatesRecruiting
Cleveland Clinic - Cleveland /ID# 256453Cleveland, Ohio, United StatesRecruiting
Uza /Id# 255114Edegem, Antwerpen, BelgiumRecruiting

+ 73 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05995353